Biosimilar rituximab and insulin glargine on the PBS and other PBS Listing changes - information for health professionals and patients

Page last updated: 14 November 2019

Biosimilar brands of rituximab (Riximyo®) and insulin glargine (Semglee®) have listed on the PBS on 1 October 2019. A biosimilar brand of trastuzumab (Herzuma®) listed on the PBS on 1 November 2019. Information for health professionals and patients can be found on the Biosimilar Awareness Initiative web page, together with information on revised PBS listings for other biological medicines.  Additionally, PBS listings have been changed for infliximab, trastuzumab and filgrastim to reflect recent recommendations by the Pharmaceutical Benefits Advisory Committee (PBAC) with regard to prescribing authority levels and substitution between brands.